Fast Five Quiz: Scleroderma Systemic Sclerosis ILD Presentation and Diagnosis

Zab Mosenifar, MD


January 28, 2022

Patients with SSc who have positive anti-topoisomerase (Scl-70) antibodies, may be at greater risk of developing ILD and disease progression, compared with limited cutaneous systemic sclerosis or positive anti-centromere antibodies.

The majority of patients with SSc-ILD have positive antinuclear antibodies, which may be accompanied by anti-topoisomerase I (anti-Scl-70), anti-Th/To, anti-U3 ribonucleoprotein (RNP), anti-U11/U12 RNP or, rarely, anti-centromere antibodies.

Other risk factors for progression in Ssc-ILD include presence of diffuse disease, extent of parenchymal disease on HRCT of more than 20%, FVC of less than 70%, and the detection of anti-topoisomerase antibody.

Learn more about CTD-ILD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.